ArticleFrontiers in pharmacology2026
Ultrasound-engineered chitosan nanocarriers improve the anticancer activity of dandelion phytochemicals in hepatocellular carcinoma cells.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: HCC remains a leading cause of cancer-related mortality, with limited effective and safe treatment options. Although dandelion ( Methods: UA-ChNPs/DE nanoparticles were synthesized using an ultrasound-assisted ionic gelation method. Physicochemical properties were characterized using dynamic light scattering, SEM, and XRD. The Results: The optimized UA-ChNPs/DE exhibited a nanoscale particle size (∼105 nm), a narrow size distribution (PDI = 0.268), and a positive surface charge (+28.4 mV), indicating colloidal stability. Structural analysis confirmed successful encapsulation and partial amorphization of the phytochemical constituents. The nanoformulation demonstrated sustained release over 72 h with a reduced initial burst release compared with the free extract. Biological evaluation revealed significantly enhanced antiproliferative activity, with UA-ChNPs/DE achieving lower IC Conclusion: UA-ChNPs effectively overcome key physicochemical and pharmacokinetic limitations of dandelion-derived compounds, resulting in improved anticancer efficacy, sustained-release behavior, and preferential cytotoxicity toward hepatocellular carcinoma cells. This nanoformulation represents a promising strategy for advancing plant-derived therapeutics in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.